Enantioselective Reductive Alkenylation of α‐CF2H (‐CF3) Amino Halides: Rapid Access to Chiral α‐CF2H (‐CF3) Allylamines

Peng Liu; Kuiliang Li; Yan He; Chen‐Hui Jiang; Ruo‐Xing Jin; Duo‐Duo Hu; Wei‐Cheng Zhao; Xuan Nie; Shang‐Zheng Sun; Xi‐Sheng Wang

doi:10.1002/advs.73986

. 2026 Jan 28;13(18):e73986. doi: 10.1002/advs.73986

Enantioselective Reductive Alkenylation of α‐CF₂H (‐CF₃) Amino Halides: Rapid Access to Chiral α‐CF₂H (‐CF₃) Allylamines

Peng Liu ^1,², Kuiliang Li ³, Yan He ², Chen‐Hui Jiang ², Ruo‐Xing Jin ², Duo‐Duo Hu ³, Wei‐Cheng Zhao ², Xuan Nie ^1,^✉, Shang‐Zheng Sun ^2,^✉, Xi‐Sheng Wang ^1,^2,^✉

PMCID: PMC13042639 PMID: 41604543

ABSTRACT

The incorporation of fluoroalkyl groups into drug candidates has garnered increasing attention in the pharmaceutical industry due to their ability to modulate lipophilicity, permeability, metabolic stability, and binding affinity. Despite significant advances realized, the means to introducing fluoroalkyl groups such as ─CF₂H or ─CF₃ in an enantioselective manner remain scarce. Herein, we report a Ni‐catalyzed enantioselective reductive alkenylation of α‐CF₂H or ─CF₃ amino chlorides with vinyl iodides. This method provides an efficient and modular technique for constructing stereocenters bearing a fluoroalkyl group. A key to success was the incorporation of an arylamide moiety with the substrates, which stabilizes the α‐fluoroalkyl radical intermediate, thus offering a de novo approach to access enantioenriched α‐CF₂H (─CF₃) allylamines. Our protocol is characterized by its mild reaction conditions, broad substrate scope, as well as excellent enantio—and chemo‐selectivity, even in the context of late‐stage functionalization.

Keywords: α‐CF₂H amines, CF₂H synthons, enantioselective, nickel catalysis, reductive coupling

Difluoromethyl (CF₂H) group, the bioisostere of hydroxyl thiol methyl or amide is privileged in medicinal chemistry due to hydrogen‐binding ability and lipophilic, metabolically stable, and chemical inert nature. However, enatioseleceive CF₂H introduction remains challenging. We report a modular approach for the constructing stereocenters bearing CF₂H or CF₃ groups via Ni‐catalyzed asymmetric reductive alkenylation of α‐CF₂H or ‐CF₃ amino chlorides with vinyl iodides.

1. Introduction

In modern drug development, the optimization of physicochemical and ADME (absorption, distribution, metabolism, excretion) properties of lead compounds and drug‐like molecules plays a crucial role [1, 2]. Among various strategies, the bioisosteric replacement is a widely employed approach as it often leads to drug candidates with enhanced potency [3]. Driven by this, chemists have recently been challenged to design general and efficient techniques for the synthesis of bioisosteric analogues. The incorporation of fluoroalkyl moieties into drug molecules can confer significant benefits, as they can modulate lipophilicity, membrane permeability, metabolic stability, and enhance protein‐drug interactions [4, 5, 6, 7, 8, 9]. In particular, difluoromethyl (CF₂H) group, the bioisostere of hydroxyl (‐OH), thiol (‐SH), methyl (‐Me) or amide group has emerged as privileged group in medicinal chemistry due to its ability to participate hydrogen‐binding interactions as well as its lipophilic, metabolically stable and chemical inert nature (Scheme 1a,b) [10, 11, 12, 13]. Indeed, a significant increase of CF₂H containing lead compounds have been developed, including FDA‐ approved drugs in recent years (Scheme 1a) [12].

SCHEME 1 — The synthesis of chiral α‐fluoroalkyl amine moieties.

Although advanced techniques for accessing enantioenriched sp³ C−CF₃ architectures [14, 15, 16, 17, 18, 19], the introducing CF₂H group into organic molecules in an enantioselective manner ‐even in the context of late‐stages—remains rare [20, 21]. This paucity is likely due to the limited availability of CF₂H regents or precursors. Driven by the prevalence of alkyl amine in pharmaceuticals and preclinical candidates, the design of a general approach for constructing enantioenriched α‐CF₂H centers in alkyl amines has gained increasing interest and would offer significant advantages in organic synthesis and medicinal chemistry [22, 23, 24]. While reductive couplings of imines are established for alkyl amines synthesis, the synthesis of fluoroalkyl‐substituted alkyl amines by this strategy has received far less attention [25, 26]. At present, existing methods for constructing chiral α‐CF₂H amines are based on nucleophilic addition with α‐CF₂H ketoimines [27, 28, 29] or difluorocarbene (Scheme 1b) [30]. However, these approaches either have limited scope, moderate enantioselectivity, or require using difluoromonochloromethane—an environmentally unfriendly gas—as a precursor. Very recently, Liu and co‐workers disclosed an enantioselective Ni‐catalyzed decarboxylative difluoromethylation of α‐amino acid derived redox esters with difluoromethyl zinc reagent (Scheme 1c, left) [31]. Simultaneously, our group developed an asymmetric difluoroalkylation of isoindolinone protected α‐CF₂H synthons with arylzinc reagents (Scheme 1c, right) [32]. These methods, while efficient for the preparation of chiral α‐CF₂H amines, suffer from the utilization of air‐ and moisture‐sensitive organometallics as well as the requirement of a multistep deprotection for the latter.

To address these challenges, we wondered whether an enantioselective difluoroalkylation could be implemented using easily available starting materials via asymmetric reductive coupling techniques [33, 34, 35]. If successful, this would offer a new strategic approach for the rapid construction of chiral α‐CF₂H amines [36]. In our continuing interest in nickel‐catalyzed reductive couplings, we report herein the successful realization of this goal (Scheme 1d) [37, 38, 39]. The utilization of new CF₂H and CF₃ synthons offers an efficient technique for the synthesis of enantioenriched α‐CF₂H or ‐CF₃ allylamines in a modular fashion. This protocol is distinguished by its mild conditions, broad substrate scope, and excellent enantio‐ & chemo‐selectivity. Mechanistic studies reveal that an α‐amino‐stabilized fluoroalkyl radical intermediate participates in the stereoselective C─C bond formation. This technique highlights the advantage of using fluoroalkyl synthons for the enantioselective functionalization of fluoroalkyl open‐shell intermediates.

2. Result and Discussion

We began our investigation by evaluating the enantioselective reductive coupling using N‐(1‐chloro‐2,2‐difluoroethyl)benzamide (1a) as the CF₂H‐containing coupling partner with methyl (E)‐4‐(2‐iodovinyl)benzoate (2a) (Table 1 ). Careful evaluation of all reaction parameters revealed the critical role exerted by the nature and substitution pattern of the ligand backbone. Indeed, the utilization of bis‐oxazoline ligand (L1), or box‐type ligand L2‐5 gave the desired product in low yields and enantiomeric excess (ee). To our delight, the 4,5‐diphenyl substituted bis(oxazoline) ligands provided promising results, with the benzyl group on the tether (L7) improved the ee value to 55%. Gratifyingly, the utilization of a more sterically encumbered group instead of a benzyl group on the tether led to a significant increase in both yield and enantioselectivity (L8, L9), with L9 providing 3a in 66% yield and 90% ee. However, the inclusion of di‐phenyl groups at the C5 position of bis(oxazoline) ligands (L10‐L12) significantly inhibited the reactivity, resulting in only trace amount product. Gratifyingly, employing TMSCl instead of TBAI as additives led to comparable yield and superior enantioselectivity (Table 1, entries 7–8). Moreover, the solvent choice was also crucial for success, as replacing THF with other common solvents drastically decreased both reactivity and enantioselectivity (Table 1, entries 1–4). As anticipated, extending the reaction time to 48 h, the desired product was obtained in 87% yield without erosion of the enantioselectivity (Table 1, entry 11). Importantly, nickel sources, reductant, additives, and solvents other than NiBr₂· DME, Mn (2.0 equiv), TMSCl (0.8 equiv), and THF resulted in either lower yields or inferior ee (Table 1, entries 1–10). More details on the additional optimization of reaction conditions can be found in Tables S1–S7.

TABLE 1.

Optimization of reaction conditions.

Entry	Ni cat.	solvent	additive	yield (%) ^b	ee (%) ^c
1	NiBr₂· DME	DME	TBAI	54	87
2	NiBr₂· DME	2‐Me THF	TBAI	41	89
3	NiBr₂· DME	Diglyme	TBAI	64	81
4	NiBr₂· DME	DMF	TBAI	10	59
5	NiBr₂· DME	THF	NaI	63	86
6	NiBr₂· DME	THF	KI	57	88
7	NiBr₂· DME	THF	TMSCl	60	97
8 ^d	NiBr₂· DME	THF	TMSCl	65	97
9 ^d	NiCl₂· DME	THF	TMSCl	41	92
10 ^d	NiBr₂	THF	TMSCl	N.D.	—
11 ^{d, e}	NiBr₂· DME	THF	TMSCl	87 (82) ^f	98

Open in a new tab

^{^a}

Unless otherwise noted, all reactions were performed with 1a (0.12 mmol, 1.2 equiv), 2a (0.1 mmol, 1.0 equiv), Ni cat. (0.01 mmol, 10 mol%), chiral ligand L (0.013 mmol, 13 mol%), Mn (2.0 equiv), additive (0.5 equiv), THF (1 mL), under Ar, at ‐20°C for 24 h.

^{^b}

Yields were determined by ¹H NMR analysis of crude mixture with CH₂Br₂ as internal standard.

^{^c}

Enantiomeric excess (ee) values were determined by HPLC on a chiral stationary phase.

^{^d}

TMSCl (0.8 equiv) was used.

^{^e}

48 h.

^{^f}

Isolated yield.

Encouraged by these initial findings, we turned our attention to studying the generality of our enantioselective reductive alkenylation of α‐CF₂H amino chlorides with vinyl iodides. As shown in Scheme 2, a diverse array of aryl‐conjugated vinyl iodides with ortho‐, meta‐, and para‐ substituents, regardless of whether electron‐donating or electron‐withdrawing groups on the aromatic ring, were efficiently converted into desired products in moderate to good yields and with excellent enantioselective control (3a‐3q). The absolute stereochemistry of the products was unequivocally confirmed by X‐ray crystallographic analysis of 3d [40]. The chemoselectivity of our reaction is illustrated by the compatibility in the presence of ester (3a, 3b, 3q), cyano (3c, 3d), ketone (3i), sulfone (3j), among others. Notably, aryl halides (3f, 3 g, 3 h) could all be well accommodated, thus providing ample opportunities for further derivatization via conventional cross‐coupling reactions. Next, we evaluated the influence the α‐CF₂H amino chlorides precursors on the catalytic asymmetric alkenylation events. Gratifyingly, the substituents on the phenyl ring of the aryl amides were largely inconsequential to the reactivity and stereoselectivity profile (3r–3ad). Importantly, the N,N‐disubstituted substrate such as 2‐(1‐chloro‐2,2‐difluoroethyl) isoindolin‐1‐one underwent targeted reaction in good yield with only slightly low enantioselectivity (70% yield, 87% ee), indicating that the steric effect of the protecting group might not compromise the reactivity or stereoselectivity (3ae). Motivated by the favorable functional group compatibility demonstrated in our reactions, we set out to explore the potential application of this transformation in the late‐stage diversification of biologically active molecules. Accordingly, we subjected a series of “drug‐like” vinyl iodides to this asymmetric alkenylation protocol. We were pleased to find that the vinyl halides derived from isoxepac (3af), fenofibrate (3ag), naproxen (3ah), gemfibrozil (3al), clofibric (3aj), and (S)‐ibuprofen (3ak) were perfectly accommodated, furnishing the chiral α‐CF₂H allylamines in good yield and excellent enantioselectivity (up to 98% ee).

SCHEME 2 — Scope of enantioselective reductive alkenylation of α‐CF₂H amino chlorides with vinyl iodides.^aReaction conditions were as follows: 1 (0.24 mmol, 1.2 equiv), 2 (0.2 mmol, 1.0 equiv), NiBr₂·DME (0.02 mmol, 10 mol%), L9 (0.026 mmol, 13 mol%), TMSCl (0.16 mmol, 0.8 equiv), Mn (2.0 equiv), THF (2.0 mL), Ar, −20°C. Isolated yields. The ee values were determined by HPLC analysis on a chiral stationary phase.

Driven by the prevalence of the trifluoromethyl (‐CF₃) group in pharmaceuticals and preclinical candidates, we wondered whether our enantioselective reductive coupling technique could be extended to α‐CF₃ containing alkyl halides [41]. Gratifyingly, this was the case; the treatment of the reaction at −40°C was crucial for success, providing α‐CF₃ allylamines in good yields with high levels of enantioselectivity (Scheme 3). The structure of 5a was unambiguously confirmed by X‐ray crystallographic analysis [42]. As shown, the reaction could also accommodate ester (5a, 5b, 5g‐5i), cyano (5c, 5d), trifluoromethyl (5e), aryl halides (5f), among others. However, this reaction presents poor compatibility with electron‐deficient vinyl iodides due to their slow oxidative addition ability with nickel species. As expected, the target enantioselective sp³ −sp² bond formation could be extended to other aryl carboxylic acids protected α‐CF₃ amines (5j‐5r). The applicability of this transformation is further illustrated in the preparation of derivatives from (L)‐menthol (5s), majantol (5t), geraniol (5u), leaf alcohol (5v), and (L)‐citronellol (5w).

SCHEME 3 — Scope of enantioselective reductive alkenylation of α‐CF₃ amino chlorides with vinyl iodides.^aReaction conditions were as follows: 4 (0.28 mmol, 1.4 equiv), 2 (0.2 mmol, 1.0 equiv), NiBr₂·DME (0.02 mmol, 10 mol%), L9 (0.026 mmol, 13 mol%), TMSCl (0.16 mmol, 0.8 equiv), THF (1.2 mL), Ar, ‐40°C. Isolated yields. The ee values were determined by HPLC analysis on a chiral stationary phase.

Furthermore, the results shown in Scheme 4 illustrate the synthetic value of our protocol. As shown in Scheme 4a, our reaction could be scaled up without an erosion in yield and enantioselectivity under standard conditions. The corresponding products 3a and 5a were obtained with 74% and 65% yield, accompanied by an excellent ee value (99% ee and 92% ee), respectively. Moreover, the unsaturated double bond could be directly hydrogenation under mild conditions, furnishing chiral fluoroalkyl amides (6a and 7a) in good yield and enantioselectivity. In addition, the successful preparation of 6e from 3e was achieved by a sequence of simple Pd/C reduction followed by BH₃ reduction, further illustrating the potential that our technique might have for accessing chiral fluoroalkyl amines with a high level of enantioselectivity (Scheme 4b).

Next, we conducted preliminary experiments to gather indirect evidence about the mechanism of our asymmetric reductive coupling reactions. As shown in Scheme 4c, when the reaction was conducted in the presence of 2.0 equivalents of TEMPO, the formation of the desired product was entirely suppressed. Additionally, HRMS analysis of the crude reaction mixture revealed the formation of TEMPO adducts, suggesting the reaction mechanism involves a SET step leading to the generation of α‐CF₂R amino radical intermediate. We also considered the possibility of the involvement of α‐CF₂R imine intermediate [43]. To evaluate this scenario, α‐CF₃ imine 8 was subjected to the standard conditions. The desired product 5a was not detected in the crude mixture, thereby demonstrating that α‐CF₃ imines are unlikely intermediates. To further understand the origin of the enantioselectivity, we performed density functional theory (DFT) calculations. As shown, with L9 as the chiral ligand, the transition state TS‐R , which leads to the formation of Pro‐R , proceeds with a lower activation barrier (∆G^‡ = 5.3 kcal/mol) compared with its counterpart, TS‐S (∆G^‡ = 6.6 kcal/mol), indicating that the R configuration of two enantiomers was favored under ligand regulation (Scheme 4e). Based on the experimental results and precedents in asymmetric nickel catalysis, we postulate a reaction mechanism as outlined in Scheme 4f [14, 17, 34]. The catalytic cycle is initiated by oxidative addition of substrate 2 to the Ni(0) center coordinated by the chiral ligand *L9, forming Ni(II)/*L9 complex B, and followed by recombination with the open‐shell intermediate E. Reductive elimination from C delivers enantioenriched product and Ni(I)/*L9 (D), which triggers a SET to 1, leading to Ni(II)/*L9 (F) that ultimately regenerates the propagating Ni(0)/*L9 (A) with Mn.⁴⁴

3. Conclusion

In summary, we have developed an efficient and versatile Ni‐catalyzed asymmetric reductive alkenylation of α‐CF₂H (‐CF₃) amine halides with vinyl halides, enabling the rapid synthesis of a wide range of enantioenriched α‐CF₂H and α‐CF₃ containing allylamines. The method is characterized by its mild conditions, broad substrate scope, and excellent enantio‐ & chemo‐selectivity, even in the context of late‐stage functionalization. This technique highlights the benefit of using fluoroalkyl containing synthons for the enantioselective functionalization of fluoroalkyl open‐shell intermediates. We anticipate that this method will be valuable to the medicinal chemistry community and will accelerate the discovery of drug candidates containing CF₂H and other fluoroalkyl stereocenters.

Conflicts of Interest

The authors declare no conflict of interest.

Supporting information

Supporting File: advs73986‐sup‐0001‐SuppMat.docx.

ADVS-13-e73986-s001.docx^{(108.7MB, docx)}

Acknowledgements

We gratefully acknowledge the National Key R&D Program of China (No. 2021YFF0701700), the National Science Foundation of China (No. 22271264, 21971228, 52203196), and the startup funding from University of Science and Technology of China (USTC) for financial support. The numerical calculations in this paper have been done on the supercomputing system in the Supercomputing Center of University of Science and Technology of China. The AI‐driven experiments, simulations and model training were performed on the robotic AI‐Scientist platform of Chinese Academy of Science.

Contributor Information

Xuan Nie, Email: niexuan@ustc.edu.cn.

Shang‐Zheng Sun, Email: ssun123@ustc.edu.cn.

Xi‐Sheng Wang, Email: xswang77@ustc.edu.cn.

Data Availability Statement

The data that support the findings of this study are available in the Supporting Information of this article.

References

1. Meanwell N. A., “Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design,” Journal of Medicinal Chemistry 54 (2011): 2529–2591, 10.1021/jm1013693. [DOI] [PubMed] [Google Scholar]
2. Lipinski C. A., Lombardo F., Dominy B. W., and Feeney P. J., “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings 1PII of Original Article: S0169‐409X(96)00423‐1. The article was Originally Published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1,” Advanced Drug Delivery Reviews 46 (2001): 3–26, 10.1016/S0169-409X(00)00129-0. [DOI] [PubMed] [Google Scholar]
3. Shultz M. D., “Two Decades Under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs,” Journal of Medicinal Chemistry 62 (2019): 1701–1714, 10.1021/acs.jmedchem.8b00686. [DOI] [PubMed] [Google Scholar]
4. Schlosser M., “CF 3 ‐Bearing Aromatic and Heterocyclic Building Blocks,” Angewandte Chemie International Edition 45 (2006): 5432–5446, 10.1002/anie.200600449. [DOI] [PubMed] [Google Scholar]
5. Müller K., Faeh C., and Diederich F., “Fluorine in pharmaceuticals: Looking Beyond intuition,” Science 317 (2007): 1881–1886. [DOI] [PubMed] [Google Scholar]
6. Purser S., Moore P. R., Swallow S., and Gouverneur V., “Fluorine in Medicinal Chemistry,” Chemical Society Reviews 37 (2008): 320–330, 10.1039/B610213C. [DOI] [PubMed] [Google Scholar]
7. Berger R., Resnati G., Metrangolo P., Weber E., and Hulliger J., “Organic Fluorine Compounds: A great Opportunity for Enhanced Materials Properties,” Chemical Society Reviews 40 (2011): 3496–3508, 10.1039/c0cs00221f. [DOI] [PubMed] [Google Scholar]
8. Kalita S. J., Qi J., Xiao L., Saha D., Huang Y.‐Y., and Shibata N., “Recent Advances on Catalytic Asymmetric Synthesis of Molecules Bearing a Fluorine‐Containing Stereogenic Carbon Center (2015–2024),” Chemical Reviews 125 (2025): 8477–8654, 10.1021/acs.chemrev.5c00177. [DOI] [PubMed] [Google Scholar]
9. Ni C. F. and Hu J. B., “The Unique Fluorine Effects in Organic Reactions: Recent Facts and Insights Into Fluoroalkylations,” Chemical Society Reviews 45 (2016): 5441–5454, 10.1039/C6CS00351F. [DOI] [PubMed] [Google Scholar]
10. Zafrani Y., Yeffet D., Sod‐Moriah G., et al., “Difluoromethyl Bioisostere: Examining the “Lipophilic Hydrogen Bond Donor” Concept,” Journal of Medicinal Chemistry 60 (2017): 797–804, 10.1021/acs.jmedchem.6b01691. [DOI] [PubMed] [Google Scholar]
11. Glyn R. J. and Pattison G., “Effects of Replacing Oxygenated Functionality With Fluorine on Lipophilicity,” Journal of Medicinal Chemistry 64 (2021): 10246–10259, 10.1021/acs.jmedchem.1c00668. [DOI] [PubMed] [Google Scholar]
12. Narjes F., Koehler K. F., Koch U., et al., “A Designed P1 Cysteine Mimetic for Covalent and Non‐Covalent Inhibitors of HCV NS3 Protease,” Bioorganic & Medicinal Chemistry Letters 12 (2002): 701–704, 10.1016/S0960-894X(01)00842-3. [DOI] [PubMed] [Google Scholar]
13. Hanan E. J., Braun M. G., Heald R. A., et al., “Discovery of GDC‐0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα,” Journal of Medicinal Chemistry 65 (2022): 16589–16621, 10.1021/acs.jmedchem.2c01422. [DOI] [PubMed] [Google Scholar]
14. Min Y., Sheng J., Yu J. L., et al., “Diverse Synthesis of Chiral Trifluoromethylated Alkanes via Nickel‐Catalyzed Asymmetric Reductive Cross‐Coupling Fluoroalkylation,” Angewandte Chemie International Edition 60 (2021): 9947–9952, 10.1002/anie.202101076. [DOI] [PubMed] [Google Scholar]
15. Zhou P., Li X. X., Wang D., and Xu T., “Dual Nickel‐ and Photoredox‐Catalyzed Reductive Cross‐Coupling to Access Chiral Trifluoromethylated Alkanes,” Organic Letters 23 (2021): 4683–4687, 10.1021/acs.orglett.1c01420. [DOI] [PubMed] [Google Scholar]
16. He Y., Bian K. J., Wu B. B., Liu P., Ni S. X., and Wang X.‐S., “Ligand‐Promoted, Enantioconvergent Synthesis of Aliphatic Alkanes Bearing Trifluoromethylated Stereocenters via Hydrotrifluoroalkylation of Unactivated Alkenes,” Chinese Journal of Chemistry 40 (2022): 1531–1536, 10.1002/cjoc.202200142. [DOI] [Google Scholar]
17. Wu B. B., Xu J., Bian K. J., Gao Q., and Wang X. S., “Enantioselective Synthesis of Secondary β‐Trifluoromethyl Alcohols via Catalytic Asymmetric Reductive Trifluoroalkylation and Diastereoselective Reduction,” Journal of the American Chemical Society 144 (2022): 6543–6550, 10.1021/jacs.2c01422. [DOI] [PubMed] [Google Scholar]
18. Jin R. X., Wu B. B., Bian K. J., et al., “Asymmetric Construction of Allylicstereogenic Carbon Center Featuring a Trifluoromethyl Group via Enantioselective Reductive Fluoroalkylation,” Nature Communications 13 (2022): 7035, 10.1038/s41467-022-34841-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Lu S. Y., Hu Z. H., Wang D., and Xu T., “Halogen‐Atom Transfer Enabled Catalytic Enantioselective Coupling to Chiral Trifluoromethylated Alkynes via Dual Nickel and Photocatalysis,” Angewandte Chemie International Edition 63 (2024): 202406064, 10.1002/anie.202406064. [DOI] [PubMed] [Google Scholar]
20. Ding D., Yin L., Poore A. T., et al., “Enantioconvergent Copper‐Catalysed Difluoromethylation of Alkyl Halides,” Nature Catalysis 7 (2024): 1372–1381, 10.1038/s41929-024-01253-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Ding D., Chen S., Yin L., et al., “Synthesis of Chiral Difluoromethyl Cyclopropanes Through Desymmetric Difluoromethylation of Cyclopropenes Enabled by Enantioselective Copper Catalysis,” Nature Synthesis 4 (2025): 1118–1127, 10.1038/s44160-025-00809-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Swarna V. M., Undem B. J., and Korlipara V. L., “Design and Synthesis of 3,5‐Disubstituted Benzamide Analogues of DNK333 as dual NK1/NK2 Receptor Probes,” Bioorganic & Medicinal Chemistry Letters 17 (2007): 890–894, 10.1016/j.bmcl.2006.11.064. [DOI] [PubMed] [Google Scholar]
23. Blakemore D. C., Castro L., Churcher I., et al., “Organic Synthesis Provides Opportunities to Transform Drug Discovery,” Nature Chemistry 10 (2018): 383, 10.1038/s41557-018-0021-z. [DOI] [PubMed] [Google Scholar]
24. Reddy K. H. V., Bédier M., and Bouzbouz S., “Efficient and Direct Synthesis of γ‐Amino‐α,β‐Unsaturated Amides by Catalyzed Allylic Substitution of α‐Fluoroenamides: Toward to Synthesis of Hybrid Peptides and Indolizidines,” European Journal of Organic Chemistry 2018 (2018): 1455–1459, 10.1002/ejoc.201800110. [DOI] [Google Scholar]
25. Xia T. T., Wu Y. H., Hu J. T., Wu X. Q., Qu J. P., and Chen Y. F., “Cobalt‐Catalyzed Asymmetric Aza‐Nozaki–Hiyama–Kishi (NHK) Reaction of α‐Imino Esters with Alkenyl Halides,” Angewandte Chemie International Edition 64 (2025): 202316012. [DOI] [PubMed] [Google Scholar]
26. Zhou P., Wang P. G., Zhu H. G., Zhang J., Peng Q., and Tao Z. L., “Dinickel‐Catalyzed Enantioselective Reductive Addition of Imines With Vinyl Halides,” Nature Communications 16 (2025): 8871, 10.1038/s41467-025-63940-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Funabiki K., Nagamori M., Goushi S., and Matsui M., “First Catalytic Asymmetric Synthesis of β‐amino‐β‐polyfluoroalkyl ketones via Proline‐Catalysed Direct Asymmetric Carbon–Carbon Bond Formation Reaction of Polyfluoroalkylated Aldimines,” Chemical Communications (2004): 1928–1929, 10.1039/B406000H. [DOI] [PubMed] [Google Scholar]
28. Liu Y. L., Shi T. D., Zhou F., Zhao X. L., Wang X., and Zhou J., “Organocatalytic Asymmetric Strecker Reaction of Di‐ and Trifluoromethyl Ketoimines. Remarkable Fluorine Effect,” Organic Letters 13 (2011): 3826–3829, 10.1021/ol201316z. [DOI] [PubMed] [Google Scholar]
29. Liu Y. L., Liu J. W., Huang Y. G., and Qing F. L., “Lewis Acid‐Catalyzed Regioselective Synthesis of Chiral α‐fluoroalkyl Amines via Asymmetric Addition of silyl Dienolates to Fluorinated Sulfinylimines,” Chemical Communications 49 (2013): 7492–7494, 10.1039/c3cc43741h. [DOI] [PubMed] [Google Scholar]
30. Peng L. Z., Wang H. Y., and Guo C., “Copper‐Catalyzed Enantioselective Difluoromethylation of Amino Acids via Difluorocarbene,” Journal of the American Chemical Society 143 (2021): 6376–6381, 10.1021/jacs.1c02697. [DOI] [PubMed] [Google Scholar]
31. Zhao X., Wang C., Yin L. F., and Liu W., “Highly Enantioselective Decarboxylative Difluoromethylation,” Journal of the American Chemical Society 146 (2024): 29297–29304, 10.1021/jacs.4c11257. [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Liu P., He Y., Jiang C. H., et al., “CF2H‐Synthon Enables Asymmetric Radical Difluoroalkylation for Synthesis of Chiral Difluoromethylated Amines,” Nature Communications 16 (2025): 599, 10.1038/s41467-025-55912-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Yi L., Ji T. F., Chen K. Q., Chen X. Y., and Rueping M., “Nickel‐Catalyzed Reductive Cross‐Couplings: New Opportunities for Carbon–Carbon Bond Formations Through Photochemistry and Electrochemistry,” CCS Chem 2022 4: 9–30. [Google Scholar]
34. Poremba K. E., Dibrell S. E., and Reisman S. E., “Nickel‐Catalyzed Enantioselective Reductive Cross‐Coupling Reactions,” ACS Catalysis 10 (2020): 8237–8246, 10.1021/acscatal.0c01842. [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Xu Y., Zu W., and Huo H., “Photo‐ and Electrochemical Asymmetric Cross‐Electrophile Couplings,” Chemcatchem 17 (2025): 202500061, 10.1002/cctc.202500061. [DOI] [Google Scholar]
36.“Nickel‐Catalyzed Asymmetric Reductive Arylation of α‐Amino‐CF 3 Acetates: A Strategy for the Enantioselective Synthesis of α‐Trifluoromethyl Amine Derivatives,” ACS Catalysis 15 (2025): 17558–17567, 10.1021/acscatal.5c06406. [DOI] [Google Scholar]
37. Sheng J., Ni H.‐Q., Zhang H.‐R., et al., “Nickel‐Catalyzed Reductive Cross‐Coupling of Aryl Halides With Monofluoroalkyl Halides for Late‐Stage Monofluoroalkylation,” Angewandte Chemie International Edition 57 (2018): 7634–7639, 10.1002/anie.201803228. [DOI] [PubMed] [Google Scholar]
38. Sheng J., Ni H.‐Q., Ni S.‐X., et al., “Diversity‐Oriented Synthesis of Aliphatic Fluorides via Reductive C(sp 3 )−C(sp 3 ) Cross‐Coupling Fluoroalkylation,” Angewandte Chemie International Edition 60 (2021): 15020–15027, 10.1002/anie.202102481. [DOI] [PubMed] [Google Scholar]
39. Li Y.‐B., Hu D.‐D., Ren W.‐R., et al., “Hydrogen Bonding Interaction Enabled Asymmetric C─H Acylation of Trifluoroethanol by Dual Nickel/Photoredox Catalysis,” Angewandte Chemie International Edition 64 (2025): 202424324, 10.1002/anie.202424324. [DOI] [PubMed] [Google Scholar]
40. Deposition Numbers CCDC 2434050 (for 3d) Contains the Supplementary Crystallographic Data for this Paper These Data Are Provided Free of Charge By the Joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures Service .
41. Ling H., Zhou L., Jia X., Gapter L. A., Agarwal R., and Ng K. Y., “Polyporenic Acid C Induces Caspase‐8‐Mediated Apoptosis in Human Lung Cancer A549 Cells,” Molecular Carcinogenesis 48 (2009): 498–507, 10.1002/mc.20487. [DOI] [PubMed] [Google Scholar]
42. Deposition Numbers CCDC 2479658 (for 5a) Contains the Supplementary Crystallographic Data for this Paper These Data Are Provided Free of Charge By the Joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures Service .
43. Wei J., Du Z. J., Wang X., Ji C. L., Li L. J., and You Y. E., “Palladium‐Catalyzed Enantioselective Arylation of Trichloro‐ or tri‐/Difluoroacetaldimine Precursors,” Chemical Communication 2024, 60, 3303–3306. [DOI] [PubMed] [Google Scholar]
44. Turro R. F., Wahlman J. L. H., Tong Z. J., et al., “Mechanistic Investigation of Ni‐Catalyzed Reductive Cross‐Coupling of Alkenyl and Benzyl Electrophiles,” Journal of the American Chemical Society 145 (2023): 14705–14715. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting File: advs73986‐sup‐0001‐SuppMat.docx.

ADVS-13-e73986-s001.docx^{(108.7MB, docx)}

Data Availability Statement

The data that support the findings of this study are available in the Supporting Information of this article.

[advs73986-bib-0001] 1. Meanwell N. A., “Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design,” Journal of Medicinal Chemistry 54 (2011): 2529–2591, 10.1021/jm1013693. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0002] 2. Lipinski C. A., Lombardo F., Dominy B. W., and Feeney P. J., “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings 1PII of Original Article: S0169‐409X(96)00423‐1. The article was Originally Published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1,” Advanced Drug Delivery Reviews 46 (2001): 3–26, 10.1016/S0169-409X(00)00129-0. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0003] 3. Shultz M. D., “Two Decades Under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs,” Journal of Medicinal Chemistry 62 (2019): 1701–1714, 10.1021/acs.jmedchem.8b00686. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0004] 4. Schlosser M., “CF 3 ‐Bearing Aromatic and Heterocyclic Building Blocks,” Angewandte Chemie International Edition 45 (2006): 5432–5446, 10.1002/anie.200600449. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0005] 5. Müller K., Faeh C., and Diederich F., “Fluorine in pharmaceuticals: Looking Beyond intuition,” Science 317 (2007): 1881–1886. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0006] 6. Purser S., Moore P. R., Swallow S., and Gouverneur V., “Fluorine in Medicinal Chemistry,” Chemical Society Reviews 37 (2008): 320–330, 10.1039/B610213C. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0007] 7. Berger R., Resnati G., Metrangolo P., Weber E., and Hulliger J., “Organic Fluorine Compounds: A great Opportunity for Enhanced Materials Properties,” Chemical Society Reviews 40 (2011): 3496–3508, 10.1039/c0cs00221f. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0008] 8. Kalita S. J., Qi J., Xiao L., Saha D., Huang Y.‐Y., and Shibata N., “Recent Advances on Catalytic Asymmetric Synthesis of Molecules Bearing a Fluorine‐Containing Stereogenic Carbon Center (2015–2024),” Chemical Reviews 125 (2025): 8477–8654, 10.1021/acs.chemrev.5c00177. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0009] 9. Ni C. F. and Hu J. B., “The Unique Fluorine Effects in Organic Reactions: Recent Facts and Insights Into Fluoroalkylations,” Chemical Society Reviews 45 (2016): 5441–5454, 10.1039/C6CS00351F. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0010] 10. Zafrani Y., Yeffet D., Sod‐Moriah G., et al., “Difluoromethyl Bioisostere: Examining the “Lipophilic Hydrogen Bond Donor” Concept,” Journal of Medicinal Chemistry 60 (2017): 797–804, 10.1021/acs.jmedchem.6b01691. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0011] 11. Glyn R. J. and Pattison G., “Effects of Replacing Oxygenated Functionality With Fluorine on Lipophilicity,” Journal of Medicinal Chemistry 64 (2021): 10246–10259, 10.1021/acs.jmedchem.1c00668. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0012] 12. Narjes F., Koehler K. F., Koch U., et al., “A Designed P1 Cysteine Mimetic for Covalent and Non‐Covalent Inhibitors of HCV NS3 Protease,” Bioorganic & Medicinal Chemistry Letters 12 (2002): 701–704, 10.1016/S0960-894X(01)00842-3. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0013] 13. Hanan E. J., Braun M. G., Heald R. A., et al., “Discovery of GDC‐0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα,” Journal of Medicinal Chemistry 65 (2022): 16589–16621, 10.1021/acs.jmedchem.2c01422. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0014] 14. Min Y., Sheng J., Yu J. L., et al., “Diverse Synthesis of Chiral Trifluoromethylated Alkanes via Nickel‐Catalyzed Asymmetric Reductive Cross‐Coupling Fluoroalkylation,” Angewandte Chemie International Edition 60 (2021): 9947–9952, 10.1002/anie.202101076. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0015] 15. Zhou P., Li X. X., Wang D., and Xu T., “Dual Nickel‐ and Photoredox‐Catalyzed Reductive Cross‐Coupling to Access Chiral Trifluoromethylated Alkanes,” Organic Letters 23 (2021): 4683–4687, 10.1021/acs.orglett.1c01420. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0016] 16. He Y., Bian K. J., Wu B. B., Liu P., Ni S. X., and Wang X.‐S., “Ligand‐Promoted, Enantioconvergent Synthesis of Aliphatic Alkanes Bearing Trifluoromethylated Stereocenters via Hydrotrifluoroalkylation of Unactivated Alkenes,” Chinese Journal of Chemistry 40 (2022): 1531–1536, 10.1002/cjoc.202200142. [DOI] [Google Scholar]

[advs73986-bib-0017] 17. Wu B. B., Xu J., Bian K. J., Gao Q., and Wang X. S., “Enantioselective Synthesis of Secondary β‐Trifluoromethyl Alcohols via Catalytic Asymmetric Reductive Trifluoroalkylation and Diastereoselective Reduction,” Journal of the American Chemical Society 144 (2022): 6543–6550, 10.1021/jacs.2c01422. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0018] 18. Jin R. X., Wu B. B., Bian K. J., et al., “Asymmetric Construction of Allylicstereogenic Carbon Center Featuring a Trifluoromethyl Group via Enantioselective Reductive Fluoroalkylation,” Nature Communications 13 (2022): 7035, 10.1038/s41467-022-34841-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0019] 19. Lu S. Y., Hu Z. H., Wang D., and Xu T., “Halogen‐Atom Transfer Enabled Catalytic Enantioselective Coupling to Chiral Trifluoromethylated Alkynes via Dual Nickel and Photocatalysis,” Angewandte Chemie International Edition 63 (2024): 202406064, 10.1002/anie.202406064. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0020] 20. Ding D., Yin L., Poore A. T., et al., “Enantioconvergent Copper‐Catalysed Difluoromethylation of Alkyl Halides,” Nature Catalysis 7 (2024): 1372–1381, 10.1038/s41929-024-01253-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0021] 21. Ding D., Chen S., Yin L., et al., “Synthesis of Chiral Difluoromethyl Cyclopropanes Through Desymmetric Difluoromethylation of Cyclopropenes Enabled by Enantioselective Copper Catalysis,” Nature Synthesis 4 (2025): 1118–1127, 10.1038/s44160-025-00809-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0022] 22. Swarna V. M., Undem B. J., and Korlipara V. L., “Design and Synthesis of 3,5‐Disubstituted Benzamide Analogues of DNK333 as dual NK1/NK2 Receptor Probes,” Bioorganic & Medicinal Chemistry Letters 17 (2007): 890–894, 10.1016/j.bmcl.2006.11.064. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0023] 23. Blakemore D. C., Castro L., Churcher I., et al., “Organic Synthesis Provides Opportunities to Transform Drug Discovery,” Nature Chemistry 10 (2018): 383, 10.1038/s41557-018-0021-z. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0024] 24. Reddy K. H. V., Bédier M., and Bouzbouz S., “Efficient and Direct Synthesis of γ‐Amino‐α,β‐Unsaturated Amides by Catalyzed Allylic Substitution of α‐Fluoroenamides: Toward to Synthesis of Hybrid Peptides and Indolizidines,” European Journal of Organic Chemistry 2018 (2018): 1455–1459, 10.1002/ejoc.201800110. [DOI] [Google Scholar]

[advs73986-bib-0025] 25. Xia T. T., Wu Y. H., Hu J. T., Wu X. Q., Qu J. P., and Chen Y. F., “Cobalt‐Catalyzed Asymmetric Aza‐Nozaki–Hiyama–Kishi (NHK) Reaction of α‐Imino Esters with Alkenyl Halides,” Angewandte Chemie International Edition 64 (2025): 202316012. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0026] 26. Zhou P., Wang P. G., Zhu H. G., Zhang J., Peng Q., and Tao Z. L., “Dinickel‐Catalyzed Enantioselective Reductive Addition of Imines With Vinyl Halides,” Nature Communications 16 (2025): 8871, 10.1038/s41467-025-63940-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0027] 27. Funabiki K., Nagamori M., Goushi S., and Matsui M., “First Catalytic Asymmetric Synthesis of β‐amino‐β‐polyfluoroalkyl ketones via Proline‐Catalysed Direct Asymmetric Carbon–Carbon Bond Formation Reaction of Polyfluoroalkylated Aldimines,” Chemical Communications (2004): 1928–1929, 10.1039/B406000H. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0028] 28. Liu Y. L., Shi T. D., Zhou F., Zhao X. L., Wang X., and Zhou J., “Organocatalytic Asymmetric Strecker Reaction of Di‐ and Trifluoromethyl Ketoimines. Remarkable Fluorine Effect,” Organic Letters 13 (2011): 3826–3829, 10.1021/ol201316z. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0029] 29. Liu Y. L., Liu J. W., Huang Y. G., and Qing F. L., “Lewis Acid‐Catalyzed Regioselective Synthesis of Chiral α‐fluoroalkyl Amines via Asymmetric Addition of silyl Dienolates to Fluorinated Sulfinylimines,” Chemical Communications 49 (2013): 7492–7494, 10.1039/c3cc43741h. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0030] 30. Peng L. Z., Wang H. Y., and Guo C., “Copper‐Catalyzed Enantioselective Difluoromethylation of Amino Acids via Difluorocarbene,” Journal of the American Chemical Society 143 (2021): 6376–6381, 10.1021/jacs.1c02697. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0031] 31. Zhao X., Wang C., Yin L. F., and Liu W., “Highly Enantioselective Decarboxylative Difluoromethylation,” Journal of the American Chemical Society 146 (2024): 29297–29304, 10.1021/jacs.4c11257. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0032] 32. Liu P., He Y., Jiang C. H., et al., “CF2H‐Synthon Enables Asymmetric Radical Difluoroalkylation for Synthesis of Chiral Difluoromethylated Amines,” Nature Communications 16 (2025): 599, 10.1038/s41467-025-55912-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0033] 33. Yi L., Ji T. F., Chen K. Q., Chen X. Y., and Rueping M., “Nickel‐Catalyzed Reductive Cross‐Couplings: New Opportunities for Carbon–Carbon Bond Formations Through Photochemistry and Electrochemistry,” CCS Chem 2022 4: 9–30. [Google Scholar]

[advs73986-bib-0034] 34. Poremba K. E., Dibrell S. E., and Reisman S. E., “Nickel‐Catalyzed Enantioselective Reductive Cross‐Coupling Reactions,” ACS Catalysis 10 (2020): 8237–8246, 10.1021/acscatal.0c01842. [DOI] [PMC free article] [PubMed] [Google Scholar]

[advs73986-bib-0035] 35. Xu Y., Zu W., and Huo H., “Photo‐ and Electrochemical Asymmetric Cross‐Electrophile Couplings,” Chemcatchem 17 (2025): 202500061, 10.1002/cctc.202500061. [DOI] [Google Scholar]

[advs73986-bib-0036] 36.“Nickel‐Catalyzed Asymmetric Reductive Arylation of α‐Amino‐CF 3 Acetates: A Strategy for the Enantioselective Synthesis of α‐Trifluoromethyl Amine Derivatives,” ACS Catalysis 15 (2025): 17558–17567, 10.1021/acscatal.5c06406. [DOI] [Google Scholar]

[advs73986-bib-0037] 37. Sheng J., Ni H.‐Q., Zhang H.‐R., et al., “Nickel‐Catalyzed Reductive Cross‐Coupling of Aryl Halides With Monofluoroalkyl Halides for Late‐Stage Monofluoroalkylation,” Angewandte Chemie International Edition 57 (2018): 7634–7639, 10.1002/anie.201803228. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0038] 38. Sheng J., Ni H.‐Q., Ni S.‐X., et al., “Diversity‐Oriented Synthesis of Aliphatic Fluorides via Reductive C(sp 3 )−C(sp 3 ) Cross‐Coupling Fluoroalkylation,” Angewandte Chemie International Edition 60 (2021): 15020–15027, 10.1002/anie.202102481. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0039] 39. Li Y.‐B., Hu D.‐D., Ren W.‐R., et al., “Hydrogen Bonding Interaction Enabled Asymmetric C─H Acylation of Trifluoroethanol by Dual Nickel/Photoredox Catalysis,” Angewandte Chemie International Edition 64 (2025): 202424324, 10.1002/anie.202424324. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0040] 40. Deposition Numbers CCDC 2434050 (for 3d) Contains the Supplementary Crystallographic Data for this Paper These Data Are Provided Free of Charge By the Joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures Service .

[advs73986-bib-0041] 41. Ling H., Zhou L., Jia X., Gapter L. A., Agarwal R., and Ng K. Y., “Polyporenic Acid C Induces Caspase‐8‐Mediated Apoptosis in Human Lung Cancer A549 Cells,” Molecular Carcinogenesis 48 (2009): 498–507, 10.1002/mc.20487. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0042] 42. Deposition Numbers CCDC 2479658 (for 5a) Contains the Supplementary Crystallographic Data for this Paper These Data Are Provided Free of Charge By the Joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures Service .

[advs73986-bib-0043] 43. Wei J., Du Z. J., Wang X., Ji C. L., Li L. J., and You Y. E., “Palladium‐Catalyzed Enantioselective Arylation of Trichloro‐ or tri‐/Difluoroacetaldimine Precursors,” Chemical Communication 2024, 60, 3303–3306. [DOI] [PubMed] [Google Scholar]

[advs73986-bib-0044] 44. Turro R. F., Wahlman J. L. H., Tong Z. J., et al., “Mechanistic Investigation of Ni‐Catalyzed Reductive Cross‐Coupling of Alkenyl and Benzyl Electrophiles,” Journal of the American Chemical Society 145 (2023): 14705–14715. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Enantioselective Reductive Alkenylation of α‐CF₂H (‐CF₃) Amino Halides: Rapid Access to Chiral α‐CF₂H (‐CF₃) Allylamines

Peng Liu

Kuiliang Li

Yan He

Chen‐Hui Jiang

Ruo‐Xing Jin

Duo‐Duo Hu

Wei‐Cheng Zhao

Xuan Nie

Shang‐Zheng Sun

Xi‐Sheng Wang

ABSTRACT

1. Introduction

SCHEME 1.